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ABSTRACT 
 
EFFECT OF OBESITY-INDUCED TUMOR NECROSIS FACTOR ALPHA ON 
ADIPOCYTE FUNCTION 
MAY 2016 
SEOK-YEONG YU, B.S., KANGWON NATIONAL UNIVERSITY, KOREA 
M.S., UNIVERSITY OF MASSACHUSETTS, AMHERST 
Directed by Dr. Young-Cheul Kim 
 
 Obesity-induced inflammation has been linked to the onset of insulin 
resistance (IR), which is a strong risk factor for the development of T2DM. Recent 
studies have indicated that tumor necrosis factor alpha (TNFα) plays a causative role 
in obesity-mediated IR via its overexpression in adipose tissue. Moreover, TNFα has 
been shown to induce the IR and the alteration of lipid and glucose metabolism in 
adipose tissue at various levels including normal adipocyte differentiation and mature 
adipocyte function. However, the mechanisms linking TNFα-induced adipocyte 
dysfunction in chronic obesity to the IR and T2DM are largely unknown. Herein we 
report that TNFα inhibited the mRNA expression of PPARγ, which is a key nuclear 
transcriptional factor for driving preadipocyte differentiation and maintaining normal 
function of mature adipocyte. TNFα treatment suppressed preadipocyte differentiation 
by downregulating mRNAs for FAS, perilipin, GLUT4, adiponectin, PGC-1α and 
C/EBPα and also altered adipocyte function by inhibiting mRNAs for perilipin, 
GLUT4, CPT-1 and PGC-1α, while increasing the expression of IL-6 and MCP1 
mRNAs. In palmitic acid (PA)-induced in vitro hypertrophic adipocytes, we found 
that mRNA expression of inflammatory cytokines (TNFα and IL-6) was significantly 
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elevated, while the expression of mRNAs for PPARγ, perilipin and adiponectin was 
markedly reduced, suggesting that TNFα may induce dysfunctional adipocyte 
phenotypes by targeting PPARγ and its target genes. In in vivo study, mice fed high 
fat diet (HFD) for 16 weeks had adipose tissue dysfunction as reflected by significant 
reduction of protein expression for PPARγ, perilipin, FAS and FABP4, consistent 
with the results observed in in vitro hypertrophic adipocytes. Interestingly, this was 
reversed by the loss of TNFα in TNFα knockout mice, indicating that TNFα may 
induce adipocyte dysfunction via the inhibition of PPARγ and its target genes. In the 
liver, HFD significantly increased hepatic triglyceride (TG) contents, while 
decreasing de novo lipogenesis (SCD1 and FAS), whereas TNFα deficiency 
decreased TG content and de novo lipogenesis compared to HFD-fed wild-type (WT) 
mice, suggesting that TNFα-induced adipocyte dysfunction is associated with hepatic 
lipid deposition in chronic obesity. Taken together, the current findings provide new 
insights into the role of TNFα in obesity-induced inflammation and also suggest the 
TNFα as a mediator for obesity-induced IR & T2DM.  
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CHAPTER 
1. PURPOSE OF STUDY 
1.1. Overview of Hypotheses 
In chronic obesity, hypertrophic adipocytes present altered glucose & lipid 
metabolism with increased secretion and expression of proinflammatory cytokines 
such as TNFα, IL-6 and MCP1. This obesity-mediated low-grade inflammation has 
been demonstrated to be a causative factor of the onset of insulin resistance (IR) 
(Samad & Ruf, 2013), which is known to be the primary defect for the development 
of type 2 diabetes mellitus (T2DM). However, the mechanisms by which 
inflammation contributes to IR in chronic obesity remain unclear.  
Among proinflammatory cytokines, tumor necrosis factor alpha (TNFα) has 
been proposed as a major candidate gene that links obesity to the onset of IR and 
T2DM (Borst, 2004). Overexpression of TNFα in adipose tissue and elevated 
systemic TNFα levels have been observed in obese or diabetic humans and animals 
(Hotamisligil, Arner, Caro, Atkinson, & Spiegelman, 1995; Hotamisligil, Shargill, & 
Spiegelman, 1993; Moon, Kim, & Song, 2004; Salles et al., 2012; Uysal, Wiesbrock, 
Marino, & Hotamisligil, 1997). TNFα neutralization in diabetic fa/fa mouse model 
significantly improved peripheral glucose uptake in response to insulin (Hotamisligil 
et al., 1993). Likewise, insulin-mediated glucose disposal in TNFα knockout mice fed 
high fat diet (HFD) for 12 weeks was substantially higher than HFD-fed wild type 
mice (Uysal et al., 1997). In addition, circulating free fatty acids levels and hepatic 
triglyceride (TG) contents were decreased in TNFα-deficient mice, whereas adipose 
tissue weight was increased in the mice (Salles et al., 2012; Uysal et al., 1997), 
indicating that TNFα alters adipose tissue function in obesity. Furthermore, TNFα has 
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been shown to inhibit preadipocyte differentiation and mature adipocyte functions 
(PPARγ, adiponectin, GLUT4, IR, IRS-1 and perilipin) (Gao, Zuberi, Quon, Dong, & 
Ye, 2003; Hotamisligil et al., 1996; Ruan, Hacohen, Golub, Van Parijs, & Lodish, 
2002; Yanagisawa et al., 2012), suggesting that TNFα induces insulin resistance and 
adipocyte dysfunction, by, at least in part, inducing lipogenic capacity.  
Even though the underlying mechanisms by which TNFα impairs normal 
adipocyte functions are not fully understood, TNFα-induced suppression of the 
expression of PPARγ has been suggested to play a critical role (Guilherme, Virbasius, 
Puri, & Czech, 2008). However, it is still unclear if the adipocyte dysfunctions are 
directly mediated by TNFα-induced PPARγ inhibition in vitro. In addition, whether 
TNFα-suppressed PPARγ expression during preadipocyte differentiation and in 
mature adipocytes is a causative factor of IR in vivo has not been investigated.  
Therefore, the goal of this work is to elucidate the role of TNFα in adipocyte 
in vitro and in vivo to understand the potential mechanism of TNFα-induced IR and 
T2DM. Hence, the central hypothesis of this study is that TNFα induces IR in 
chronic obesity by inducing altered lipogenic capacity and adipocyte dysfunction.  
Figure 1 TNFα induces adipocyte dysfunction via the inhibition of 
PPARγ 
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1.2. Specific Aims & Hypothesis 
Specific Aim 1 is to test if TNFα induces adipocyte dysfunction and to establish and 
characterize in vitro model of hypertrophic adipocytes.  
 
I hypothesize that TNFα causes adipocyte dysfunction through PPARγ inhibition. 
Further, I hypothesize that hypertrophic adipocytes present dysfunctional 
phenotype with a decrease in PPARγ but an increase in TNFα expression 
Rationale: In the literature, TNFα has consistently inhibited preadipocyte 
differentiation as well as normal adipocyte function. However, it has been unclear if 
TNFα-induced PPARγ inhibition is involved in adipocyte dysfunction.  
 
Specific Aim 2 is to examine the role that TNFα plays in adipose tissue and to 
determine the metabolic consequences of TNFα-induced adipocyte dysfunction in 
vivo. 
 
Therefore, I hypothesize that obesity-induced TNFα induces adipose tissue 
dysfunction via PPARγ inhibition and its downstream target genes involved in 
normal adipose function in vivo.    
Rationale: In the literature, TNFα has been directly linked to IR and altered lipid 
metabolism in the whole body. However, it has not been elucidated if TNFα induces 
adipocyte dysfunction in vivo and if TNFα-induced adipocyte dysfunction is involved 
in systemic IR.  
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1.3. Significance 
 The growing prevalence of obesity and type 2 diabetes mellitus (T2DM) is a 
major leading public health problem in the U.S. and around the world and the direct 
association between obesity-induced IR and T2DM has been long recognized. 
Although the precise mechanisms and molecule(s) responsible for this link are still 
unclear, altered production of TNFα caused by excess adipose tissue have been 
known to contribute to the onset of insulin resistance (IR) and development of T2DM. 
Our findings aid in understanding the role of TNFα in obesity-induced IR & T2DM, 
which is important to help identify specific targets and molecular mechanisms for 
effective intervention and treatment.  
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2. LITERATURE REVIEW 
2.1. Obesity & diabetes 
2.1.1. Prevalence & Interrelationship  
Obesity is characterized by an excessive adipose tissue mass and is a leading 
preventable cause of death in the 21st century. The increase in adipose mass results 
from both increased adipocyte size (hypertrophy) or increased adipocyte numbers 
(hyperplasia) through adipogenesis (Salans, Cushman, & Weismann, 1973). In 2013, 
the adult population with body mass index (BMI) of 25 kg/m2 or greater (overweight) 
across 183 countries increased up to 36.9% (men) and 38.0% (women) and the 
number of obese or overweight people are becoming more prevalent in both 
developed countries (Ng et al., 2014). The prevalence of child and adolescent obesity 
has increased substantially in developing and developed countries; over 20% in 
developed countries and about 13 % in developing countries (Ng et al., 2014). In 
addition, the numbers for overweight and obese individuals are estimated to increase 
up to 1.35 billion and 573 million worldwide, respectively, by 2030 (Kelly, Yang, 
Chen, Reynolds, & He, 2008).  
Diabetes is characterized by hyperglycemia and insulin resistance and is a 
worldwide public health problem. There are three types of diabetes such as type 1 
diabetes mellitus (insulin-dependent diabetes, T1DM), type 2 diabetes mellitus (non-
insulin dependent diabetes, T2DM) and gestational diabetes. Among three types of 
diabetes, T2DM accounts for approximately 90% of all cases of diabetes. Similar to 
obesity, the prevalence of T2DM has rapidly increased since 1980 and it is estimated 
to further increase from 382 million (in 2013) to 592 million by 2035 across 130 
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countries (Guariguata et al., 2014). The global prevalence of T2DM is also becoming 
higher in both developing and developed countries (Guariguata et al., 2014).   
According to the map showing trends in diabetes & obesity from Centers for 
Disease Control and Prevention (CDC, http://www.cdc.go/diabetes/statistics), the 
growth rate of obese population (BMI≥ 30 kg/m2) in the U.S. has been almost 
doubled between 1994 and 2013; 26% or greater obese population in 38 states, 22 to 
25.9% obese population in 11 states, and 18 to 21.9% obese population in 2 states. 
Similarly, the prevalence of T2DM grew rapidly in nearly all the states; more than 9% 
diabetic population in 25 states, 7.5 to 8.9% diabetic population in 19 states and 6.0 to 
7.4% diabetic population in 7 states, and it presents a similar trend to the increase in 
obesity prevalence across all the states during the time period. Although the 
relationship between obesity & diabetes is interdependent, the clear mechanisms 
linking these two conditions remain unclear. It is therefore important to understand 
the pathogenesis of obesity-mediated T2DM for effective prevention & treatment 
options.  
 
2.1.2. Obesity-induced insulin resistance and T2DM 
Although the exact mechanism of obesity-mediated T2DM has been unclear, 
obesity-induced IR has been believed to be a critical factor that contributes to the 
development of T2DM. IR is a condition in which insulin-mediated glucose disposal 
in the body is impaired and is highly associated with the severity of obesity. Garcia-
Estevez and the co-workers (Garcı́a-Estévez, Araújo-Vilar, Saavedra-González, 
Fiestras-Janeiro, & Cabezas-Cerrato, 2004), for example, reported that insulin 
sensitivity index as measured by oral glucose tolerance test is dramatically decreased 
as BMI increased and that the amount of insulin secreted was significantly increased 
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from BMI 29.3 to 45 kg/m2, whereas this was consistent between BMI 18 to 29.3 
kg/m2. In addition, obesity-induced IR has been positively correlated with waist 
circumference (WC), plasma free fatty acids (FFAs), triglyceride (TG) and 
proinflammatory cytokines levels (Aslam, Aggarwal, Sharma, Galav, & Madhu, 2016; 
Boden & Shulman, 2002; Greco et al., 2002; Xu et al., 2015), all of which are the risk 
factors for the development of T2DM. Although most patients with T2DM are obese, 
not all obese individuals develop T2DM later in their lives, suggesting that 
environmental factors such as diets and sedentary behavior interact with a genetic 
predisposition during the development of T2DM. Therefore, identifying factors that 
underlie insulin resistance in obesity will be essential to advance the effective 
interventions. 
In an attempt to elucidate the complexity of the progression of obesity to 
T2DM, many risk factors have been investigated and identified such as circulating 
FFAs, adipokines and ectopic fat deposition to the liver and muscle (Kralisch et al., 
2007; Petersen et al., 2005; Roden et al., 1996). These factors are inter-independent 
and positively correlated with the whole-body insulin resistance in the patients with 
T2DM.   
 
Ø Free fatty acids (FFAs): Elevated plasma FFAs levels have been observed in 
obese and diabetic states. (Boden, 2011; Savage, Petersen, & Shulman, 2007). 
The concentration of FFAs in the circulation is determined by the dynamics 
between the release of FFAs from adipocytes and FFAs clearance from the 
circulation. In obesity and T2DM, however, chronically elevated FFAs inhibit 
insulin-mediated antilipolytic action and in turn perturb the turnover rate of FFAs 
in adipocytes (Bjorntorp, Bergman, & Varnauskas, 1969; Jensen, Haymond, 
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Rizza, Cryer, & Miles, 1989). This also causes insulin resistance through the 
inhibition of glucose translocation in skeletal muscle and stimulation of 
glycogenolysis, glycogen breakdown, suggesting failure of FFAs clearance 
mediate insulin resistance in obesity (Boden, Chen, Capulong, & Mozzoli, 2001; 
Dresner et al., 1999).  
 
Ø Adipokines: Adipokines refers to cytokines secreted from adipose tissue. 
Adiponectin is known as adipoQ and a key regulatory protein for systemic insulin 
sensitivity. The biological roles of adiponectin are to increase FFA oxidation in 
the liver and muscle tissues through adiponectin receptor 1 & 2 (AdipoR1 & 2) 
and also to stimulate the clearance rate of FFAs, TG and glucose from the blood 
(Cnop et al., 2003; Kadowaki & Yamauchi, 2005; Liu et al., 2012; Polyzos, 
Kountouras, Zavos, & Tsiaousi, 2010). However, the plasma level of adiponectin 
is lower in obese and diabetic individuals (Hara et al., 2003; Yu et al., 2002). 
Plasma adiponectin level is inversely correlated with plasma TG, free fatty acids 
levels and insulin resistance (Cnop et al., 2003; Engeli et al., 2003; Medina-
Urrutia et al., 2015). In in vivo study with rhesus monkeys, Hotta and the co-
workers (Hotta et al., 2001) demonstrated that plasma adiponectin levels were 
decreased in primates before the onset of diabetes and persisted even after the 
onset. By comparing the rate of glucose clearance from blood between 
hyperadiponectinemia and hypoadiponectinemia in obese monkeys, they found 
that hypoadiponectinemia had significantly lower glucose disposal rate, indicating 
adiponectin is closely associated with systemic insulin sensitivity. 
Inflammatory cytokines such as TNFα and Il-6 are also included in adipokines 
due to that they are overexpressed from adipose tissue in obese and diabetic 
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humans and animals (Barbarroja et al., 2010; Chang et al., 2015; Kern, 
Ranganathan, Li, Wood, & Ranganathan, 2001; Kuo, Chang, Tsai, & Lee, 2012). 
It could be attributed to the fact that macrophages are infiltrated into adipose 
tissue and activated while increasing the expression of proinflammatory cytokines 
(Heilbronn & Campbell, 2008). However it has been reported that enlarged and 
hypertrophic adipocytes overexpress TNFα, MCP1, IL-6, serum amyloid A 
(SAA), plasminogen activator inhibitor-1 (PAI-1), and hyaluronan (HA) in vitro 
(Han et al., 2007; Jernas et al., 2006; Kim et al., 2015). In addition, the size of 
adipocyte was highly associated with plasma IL-6, TNFα and insulin resistance in 
obese individuals (Maffeis et al., 2007). 
Taken together, these observations reinforce the function of adipose tissue in 
metabolic homeostasis through sequestration of fat and normal secretion of 
adipokines as supported by the demonstration that the loss of adipose tissue 
function increases the risk factors for T2DM (Moitra et al., 1998; Sovik, 
Vestergaard, Trygstad, & Pedersen, 1996; Vigano et al., 2011).  
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2.2. The physiological role of adipose tissue 
Adipose tissue is a specialized connective tissue that serves as a major energy 
reservoir in the body. Adipose tissue is classified into brown adipose tissue (BAT) 
and white adipose tissue (WAT) by the physiological characteristics in the body, but 
WAT is the major tissue that constructs the body’s adipose tissue. Over the past 
decade, the perspective on adipose tissue (WAT) is changed from a fat store to a 
complex endocrine organ because it secrets adipokines, such as adiponectin that plays 
an important role in the whole body energy metabolism and homeostasis.  
In adipose tissue, there are many different types of cells such as adipocyte, 
preadipocytes and non-adipose cells such as lymphocytes, neutrophils, endothelial 
cells and macrophages but adipose tissue is mainly made up of adipocytes. In our 
body, adipose tissue is distributed in many different sites throughout the body such as 
subcutaneous layers, around heart, kidneys and internal organs to provide insulation 
and mechanical support. However, the most important role of adipose tissue in the 
body is (1) to esterify and store TGs during a feeding state and (2) to de-esterify and 
release FFAs into the circulation during a fasting state. Even though the release of 
FFAs increases during a fasting state, the fasting fatty acid is taken up into the liver, 
muscle and heart to esterify with coenzyme A and to oxidize it in mitochondria. On 
the other hand, during feeding, the concentration of FFAs and glucose in the 
circulation is regulated by insulin, whose actions are to increase the uptake of glucose 
and FFAs in adipose tissue and to inhibit lipolysis in adipocytes.  
 Adipose tissue function is There are two ways to store the energy in the body, 
such as hyperplasia which is the process to increase the number of adipocytes through 
preadipocyte differentiation and adipocyte hypertrophy which is the process to 
enlarge adipocyte itself. The process of preadipocyte differentiation has been 
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investigated using reliable in vitro cell model which is 3T3-L1 preadipocyte from 3T3 
mouse embryo fibroblasts. 
 
3T3-L1 preadipocytes are differentiated into adipocyte with morphological changes 
by adipogenic cocktail including insulin, a glucocorticoid and 3-isobutyl-1-
methylxanthine. Once confluent 3T3-L1 preadipocytes are exposed to the adipogenic 
cocktail, the cells undergo a complex cell signaling event including postconfluent 
mitosis and growth arrest and differentiate into adipocytes through a series of 
transcriptional steps as described in Fig.1. Among adipogenic transcription factors, 
the importance of PPARγ has been notably known for the regulation of cell 
differentiation and metabolism such as lipogenic genes such as FAS, GLUT4 and 
adiponectin. In addition, PPARγ plays an important role in the maintenance of mature 
fat cell functions. Tamori and the co-workers (Tamori, Masugi, Nishino, & Kasuga, 
Figure 2. 	Differentiation process of 3T3-L1 preadipocytes into adipocytes 
(Ntambi & Young-Cheul, 2000) 
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2002) created PPARγ mutant 3T3-L1 adipocytes and found that the mutation of 
PPARγ in adipocytes increased the rate of lipolysis and caused a reduction in the 
uptake of free fatty acids. Also, it decreased the expression of GLUT4, insulin 
receptor, and insulin receptor substrate (IRS).  
2.3. Insulin-resistant obesity: Adipose tissue & adipocyte 
Over the past decade, it has been suggested that inflammation plays an 
important role in the onset of insulin resistant (Samad & Ruf, 2013). Recently, it has 
been increasingly evident that inflammation-induced adipocyte dysfunction links 
obesity to insulin resistance (Guilherme et al., 2008). This is also strongly supported 
by a large body of evidence that PPARγ agonist reverses adipocyte dysfunction in IR 
(Mayerson et al., 2002; Tiikkainen et al., 2004), further suggesting the role of PPARγ 
in obesity-induced IR. 
 
2.3.1. Inflammation and adipose tissue  
Adipose tissue is an insulin-sensitive tissue and the major site where the body 
stores the energy in a highest density. Adipose tissue function properly controls the 
whole body lipid and glucose metabolism in response to insulin. However, in obesity, 
prolonged excessive energy induces abnormally enlarged and hypertrophied 
adipocytes. The plasma adiponectin, which is associated with systemic insulin 
sensitivity, is downregulated and adipocyte lipolysis is stimulated (Kennedy, Martinez, 
Chuang, LaPoint, & McIntosh, 2009; Meyer, Ciaraldi, Henry, Wittgrove, & Phillips, 
2013). In addition, macrophages are infiltrated into adipose tissue and become 
activated. Vicious cycle is created between hypertrophic adipocytes and macrophages 
by secreting proinflammatory cytokines such as tumor-necrosis factor alpha (TNFα)  
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and interleukin 6 (IL-6) (Suganami & Ogawa, 2010). Therefore, low-grade 
inflammation is created in obesity and it causes insulin resistance locally and 
systemically. Among many proinflammatory cytokines, TNFα has been recently 
suspected of the causative factor that induces insulin resistance in obesity.   
 
2.3.2. The role of TNFα in obesity 
TNFα is one of the key regulators of inflammatory response and originally 
thought to be associated with cachexia. However, it has been now recognized as a 
critical factor involved in insulin resistance in obesity.  
In clinical trials, systemic TNFα levels are positively correlated with BMI, 
WC and body fat mass (%) (Moon et al., 2004). In addition, it showed a positive 
correlation with plasma insulin, glucose and the size of adipocytes (Bahceci et al., 
2007; Nilsson, Jovinge, Niemann, Reneland, & Lithell, 1998). Adipose tissue TNFα 
Figure 3. Obesity-induced hypertrophic adipocye and low-grade 
inflammation (Samad & Ruf, 2013) 
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expression is also increased in obese groups (Hotamisligil et al., 1995). In addition, it 
has shown a positive correlation with body fat (%), plasma insulin and glucose levels 
(Hotamisligil et al., 1995; Kern et al., 1995).  
In in vivo studies, fa/fa mouse model has been shown that genetically develops 
T2DM and IR with adipose tissue TNFα expression increased (Hotamisligil et al., 
1993). However, TNFα neutralization significantly improved glucose disposal in 
peripheral tissues and high concentration of the TNFα-neutralizing agent further 
increased glucose uptake into peripheral tissues in the mice (Hotamisligil et al., 1993). 
In addition, high-fat diet (HFD)-fed TNFα-deficient mice had improved insulin 
sensitivity, decreased the mRNA expression of proinflammatory cytokines (IL-6, 
MCP1 and SAA) and circulating free fatty acids (FFAs) levels (Salles et al., 2012; 
Uysal et al., 1997).  
In in vitro models, TNFα inhibited 3T3-L1 preadipocyte differentiation (Chae 
& Kwak, 2003). In mature adipocytes, TNFα inhibited insulin signaling pathway by 
decreasing the protein expression of insulin receptor substrate 1 (IRS-1) and 
increasing serine phosphorylation of insulin receptor (Hotamisligil et al., 1996). In 
addition, TNFα significantly decreased the expression levels of glucose transporter 1 
& 4 (GLUT1 & GLUT4) and adiponectin (Stephens, Lee, & Pilch, 1997). However, 
the evidence of underlying mechanisms by which TNFα alters adipocyte functions is 
unclear.   
 
2.3.3. Therapeutic approaches against the action of TNFα  
 Even though the mode of action of TNFα in IR is unclear, there have been 
many observations that synthetic and natural bioactive compounds attenuate IR in 
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obesity and T2DM. The evidence could give us an insight into the ways to prevent 
and treat IR and T2DM. 
 
Ø Drugs: Sodium salicylate, an anti-inflammatory drug, has been shown to reduce 
urinary glucose excretion in T2DM patients (Ebstein, 1876; Williamson, 1901). 
Aspirin (~ 6 g/d), one of salicylates, also causes a reduction in fasting plasma 
glucose, TG and fatty acid levels in diabetic patients (Hundal et al., 2002). But at 
low-dose between 81 to 100 mg per day aspirin did not alter the plasma 
parameters (Ogawa et al., 2008). In 3T3-L1 adipocytes, aspirin antagonized 
TNFα-induced impairment of insulin signaling pathway by blocking mediated 
NF-κB signaling pathway, which is activated by TNFα in vitro (Gao et al., 2003). 
In addition, transfected adipocytes with a non-degradable mutant of IκBα which 
blocks NF-κB signaling showed upregulation of GLUT4 (Ruan et al., 2002), 
suggesting that TNFα-mediated NF-κB signaling impairs adipocyte functions.  
TZDs are anti-diabetic drugs with insulin-sensitizing effects by targeting 
PPARγ in diabetic patients. The treatment with TZDs has been shown to reduce 
plasma TG, FFAs and insulin in obese and diabetic individuals (Mayerson et al., 
2002; Yu et al., 2002). It has also shown the antagonizing effects on the action of 
TNFα. TZDs such as pioglitazone (Pio) increased the downregulation of IRS-1 
and insulin receptor protein expression by TNFα in adipocytes in vitro (Iwata et 
al., 2001). However, Pio did not alter TNFα-mediated NF-κB signaling pathway, 
suggesting that PPARγ is an intermediate gene between NF-κB signaling 
cascades and insulin signaling pathway. However, aspirin worked at a high 
concentration that might lead to the adverse effects such as gastrointestinal tract 
bleeding and also it showed that aspirin resistance occurs commonly in diabetic 
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patients. In addition, TZDs treatment accompanies significant weight gain (Fateh-
Moghadam et al., 2005; Fonseca, 2003).  
 
Ø Bioactives: Phytoestrogens (isoflavones) are plant-derived compounds with 
partial estrogenic effects due presumably to structurally similarity to endogenous 
estrogen, estradiol. The bioactive compounds are abundant in legumes, red clover 
and soy-containing foods. Besides the partial estrogenic effects, isoflavones are 
well known for PPARs activator. In obesity, soy consumption is inversely 
correlated with the prevalence of obesity across 167 countries (Dante & Maciej, 
2012), suggesting that soy consumption lowers adiposity in the body. In vivo 
study with Zucker rat which is used as an genetically-induced obese metabolic 
syndrome model, Mezei and co-workers (Mezei et al., 2003) demonstrated that 
high-isoflavone soy protein (HIS) were significantly reduced hepatic cholesterol 
and TG levels compared to low-isoflavone soy protein (LIS) and control groups 
in male and female rats. In oral glucose tolerance test in obese Zucker rats, HIS 
also significantly improved glucose intolerance. In another genetic model (obese 
SHR/N-cp rats), isoflavones (genistein, daidzein and glycetin) administration for 
20 weeks significantly lowered plasma total cholesterol and LDL levels but 
increased HDL cholesterol levels (Ali, Velasquez, Hansen, Mohamed, & 
Bhathena, 2004). In addition, genistein or daidzein alone significantly reduced 
HFD-induced body weight and adiposity in mice (Ae Park et al., 2006), 
suggesting that isoflavones could be the beneficial factor that reduces the 
incidence of obesity. 
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In diabetes, legume and soy food intake reduced the onset of T2DM in the 
women living in the Shanghai (Villegas et al., 2008). Also, the association between a 
higher intake of soy product and a lower risk of T2DM among overweight Japanese 
women has been observed (Nanri et al., 2010). In db/db mice, genistein and daidzein 
significantly improved plasma HbA1c levels and hepatic glucokinase activity (M. S. 
Choi, Jung, Yeo, Kim, & Lee, 2008). Genistein lowered hyperglycemia and oxidative 
stress and also reduced plasma TNFα, IL 1β and IL-6 in streptozotocin (STZ)-induced 
diabetic mice (Valsecchi et al., 2011). Besides to soy isoflavones, red clover extract 
rich in formononetin and biochanin A reduced plasma TG, total and LDL-cholesterol 
levels in STZ-induced diabetic mice (Qiu, Chen, et al., 2012; Qiu, Ye, et al., 2012). 
Also isoflavones such as formononetin or biochanin A alone also attenuated plasma 
hyperlipidemia suggesting isoflavones as the bioactives exerting anti-diabetic effects. 
However, the underlying mechanism of isoflavones-induced anti-obesity or anti-
diabetic effects has remained unclear.      
Figure 4. The role of isoflavones in PPAR signaling. (Patel & Barnes, 2010)   
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3. IN VITRO STUDY: THE EFFECTS OF TNFα IN ADIPOCYTE 
FUNCTION 
3.1. Materials 
Oil Red O (ORO), palmitate, 3-isobutyl-1-methylxanthine (IBMX), dexsamethasone 
(DEX) and insulin (INS) were purchased from Sigma Chemical Co. (St Louis, MO, 
USA). Rhe fast SYBR real-time PCR master mix, TNFα Dulbecco’s modified Eagle’s 
medium (DMEM), fetal bovine serum (FBS), newborn calf serum (NCS), penicillin-
streptomycin (P/S), and trypsin-EDTA were obtained from Life Technologies (Grand 
Island, NY, USA). The specific primers for quantitative real-time PCR were designed 
using PrimerQuest (Integrated DNA Technologies; 
https://www.idtdna.com/Primerquest/Home/Index and obtained from integrated DNA 
Technologies (Coralville, Iowa, USA) and the primer sequences used are provided in 
Table 1. 
 
Table 1 PCR primer sequences for real-time PCR analysis 
PPARγ F
1) TCGGTTTCAGAAGTGCCTTG β-actin F CAGCCTTCCTTCTTGGGTATG R2) GATCTCCGCCAACAGCTTC R CGGATGTCAACDTCACACTT 
Perilipin F CCTCTGTGTGCAATGCCTAT C/EBPα F GAACGCAACAACATCGC R CTCTGCAGGCCAACTCATT R CACCTTCTGTTGCGTCT 
FAS F 
CTGTACGGGATCATACTGGTTC 
IL-6 F 
TTGCCTTCTTGGGACTGATG 
R CAGAGCGCTGGTCATGTA R AGGTCTGTTGGGAGTGGTAT 
GLUT4 F GCTTGGCTCCCTTCAGTTT MCP1 F CRCACCTGCTGCTACTCATTC R CCAGCCACGTTGCATTGTA R ACTACAGCTTCTTTGGGACAC 
AdipoQ3) F GAGAGAAGGGAGAGAAAGGAG TNFα F GCCTCCCTCTCATCAGTTCTA R CAGCTCCTGTCATTCCAACA R CACTTGGTGGTTTGCTACGA 
CPT-1 F CTGGATGTTTGCAGAGCAC DGAT1 F CCAGCAAGCTGTGAGCTAT R GCTGTACAACATGGGCTTTC R GGACCGAGGAAAGTTGAGTT 
PGC-1α F CGATCACCATATTCCAGGTCAAG ATGL F TCCAGTTCAACCTTCGCAAT R AAGGGAGAATTGCGGTGTG R CCATCTCTGTAGCCCTGTTTG 
SCD-1 F 
CACAGATGATGACAGGAGATGG 
- - R AAAGGAGGCGTCGAACTTG - 
1) Forward 
2) Reverse 
3) Adiponectin 
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3.2. Experimental design  
3.2.1. TNFα treatment during preadipocyte differentiation 
 
3T3-L1 cells (ATCC® CL-173TM) were used below passage 12. 3T3-L1 
preadipocytes were propagated and cultured in DMEM medium supplemented with 
10% NCS and 1% P/S until confluent, further maintained for additional 2 days and 
differentiated in DMEM containing 10% FBS and 1% P/S for 6 days. The medium 
was changed every other day.  
 
3.2.2. TNFα treatment in mature adipocyte 
Figure 5. Experimental design of TNFα treatment 
during 3T3-L1 preadipocyte differentiation 
Figure 6. Experimental design of TNFα treatment 
to mature adipocyte 
20		
Once 3T3-L1 preadipocytes were fully differentiated into adipocytes, the cells 
were serum-starved in serum-free, high-glucose DMEM with 1% P/S for 24 h. After 
serum starvation, the cells were exposed to TNFα for 6 h and then harvested.  
 
3.2.3. Characterization of hypertrophic adipocyte 
 
Fully differentiated adipocytes were exposed to palmitic acid (250 µM) to 
induce hypertrophic adipocytes as reported. The medium was daily changed and the 
cells were harvested after 6 days.   
 
3.3. Methods 
Ø Oil Red O (ORO) staining. To determine the degree of differentiation as 
measured by intracellular lipid content, ORO was performed. Briefly, 3T3-L1 
adipocytes were washed with 4% paraformaldehyde once and fixed with 4% 
paraformaldehyde for 20 min at room temperature. Cells were then washed with 
60% isopropanol once and stained with diluted Oil Red O solution for 30 min. 
After photographing the stained cells, the dye retained in 3T3-L1 cells was eluted 
Figure 7 Experimental design of the induction of adipocyte 
hypertrophy 
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with 100% isopropanol and absorbance was measured by a microplate reader 
(SpectraMax M2, Molecular Devices, Sunnyvale, CA) at 490 nm. 
 
Ø Quantitative real-time PCR. Total RNA was isolated with TRIzol® according to 
manufacturer’s protocol (Life technologies, Grand Island, NY). 1 µg of total 
RNA was used to synthesize cDNA using RevertAid First Strand cDNA 
Synthesis kit (Thermo Scientific, Waltham, MA). The reaction was performed 
with Fast SYBR® Green Master Mix containing 1 µM of primer pair and 100 ng 
of cDNA under 40 cycles with each of 95 °C for 1 sec and 58 °C for 20 sec. 
Relative levels of the target mRNA expression were determined by ViiATM 7 
real-time PCR system (Life technologies, Grand Island, NY), normalized to 
GAPDH or β-actin and calculated with the 2-(ΔΔnd) method. 
 
3.4. Statistical analysis.  
All statistical analyses were performed in Excel and statistical significances 
were evaluated with independent t-test.  
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3.5. Results 
3.5.1. TNFα inhibited preadipocyte differentiation.  
In order to investigate if TNFα induces adipocyte dysfunction through the 
inhibition of preadipocyte differerntiation, first the inhibitory effects of TNFα on 
preadipocyte differentiation was evaluated. Widely used concentration of TNFα, 10 
ng/mL (Chae & Kwak, 2003), was selected and preadipocytes were differentiated into 
adipocytes in presence or absence of TNFα for 6 days. The cells were then stained 
with ORO. As shown in Fig. 8, the picture of ORO stained-cells indicates that about 
50% of preadipocytes were differentiated into adipocytes at day 6 of the 
differentiation. However, the differentiation of TNFα-treated preadipocytes was 
noticeably inhibited compared to the picture of control cells. The TNFα-induced 
relative inhibition was about 60% at day 5 (p <0.001).  
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Figure 8. The effects of TNFα during 3T3-L1 preadipocyte differentiation. On 
day 5 of differentiation, intracelluar lipid droplets were stained with ORO 
solution for 30 min air-dried overnight. After then the picture of the plate with 
ORO-stained cells was scanned and eluted with 100% isopropanol. The 
expriment was repeated three times. Each bar represents a mean ± S.E. 
Significant difference was determined by independet t-test (*p<0.05 vs. control, 
**p<0.01vs. control, ***p<0.001 vs. control) 
 
3.5.2. TNFα inhibited the expression of major transcriptional factors for 
adipocyte differentiation.  
In an mRNA level, the inhibitory effects of TNFα on preadipocyte 
differentiation were confirmed. As shown in Fig. 9, TNFα significantly suppressed 
the mRNA expression levels of PPARγ and C/EBPα (p <0.001) which are the key 
nuclear transcriptional factors for preadipocyte differentiation while inducing the 
mRNA expression levels of IL-6 and MCP1 (p <0.001) which are well known for 
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TNFα target gene, suggesting that TNFα inhibits preadipocyte differentiation through 
the inhibition of endogenous elements for the differentiation.   
 
Figure 9. TNFα-induced changes in gene expression of PPARγ, C/EBPα, IL-6 
and MCP1 during preadipocyte differentiation. At day 5, the cells were 
harvested with TRizol and used for RT-PCR as described Methods. The 
expriment was repeated three times and the data resented are relative values 
expressed in relation to endogenous β-actin (mean±S.E.). Significant difference 
was determined by independent t-test (*p<0.05 vs. control, **p<0.01vs. control, 
***p<0.001 vs. control) 
 
3.5.3. PPARγ downstream target genes were inhibited in the presence of TNFα 
during preadipocyte differentiation.  
To assess if the inhibition of preadipocyte differentiation by TNFα is a 
potential mechanism for TNFα-induced adipocyte dysfunction, the genes related to 
lipid and glucose metabolism in adipocyte were analyzed. As shown in Fig. 10, TNFα 
induced a progressive decrease in the mRNA expression levels of FAS and perilipin 
(p <0.001), which are involved in lipid synthesis and coating. In addition, TNFα 
suppressed the mRNA expression levels of GLUT4 and adiponectin (p <0.001).  
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Figure 10. TNFα treatment results in the downregulation of PPARγ downstream 
target genes during preadipocyte differentiation. At day 5, the cells were 
harvested with TRizol and used for RT-PCR as described Methods. The 
expriment was repeated three times and the data resented are relative values 
expressed in relation to endogenous β-actin (mean±S.E.). Significant difference 
was determined by independent t-test (*p<0.05 vs. control, **p<0.01vs. control, 
***p<0.001 vs. control) 
 
3.5.4. PGC-1α only was inhibited by TNFα during preadipocyte differentiation.  
To ascertain the effects of TNFα-inhibited preadipocyte differentiation on 
lipid metabolism, lipid oxidation-related genes such as carnitine palmitoyltransferase 
1(CPT1) and peroxisome proliferator-activated receptor gamma coactivator 1 alpha 
(PGC-1α) were analyzed. TNFα significantly inhibited PGC-1α mRNA (p<0.001) but 
did not affect the mRNA expression of CPT-1 during preadipocyte differentiation. 
Since CPT-1 expression is not altered during preadipocyte differentiation (Brown et 
al., 1997), our data clearly indicate that TNFα impairs adipocyte functions through the 
inhibition of preadipocyte differentiation and. 
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Figure 11. TNFα does not affect the mRNA expression of CPT-1 but PGC-1α 
during preadipocyte differentiation. At day 5, the cells were harvested with 
TRizol and used for RT-PCR as described Methods. The expriment was repeated 
three times and the data resented are relative values expressed in relation to 
endogenous β-actin (mean±S.E.). Significant difference was determined by 
independent t-test (*p<0.05 vs. control, **p<0.01vs. control, ***p<0.001 vs. 
control) 
 
3.5.5. TNFα also inhibited PPARγ gene expression in mature adipocyte.  
Even though adipocyte functions are maintained through preadipocyte 
differentiation, adipose tissue functions are represented by adipocyte functions. Thus, 
the effects of TNFα on adipocyte functions were evaluated. To this end, if PPARγ 
mRNA is altered during TNFα stimulation as the endogenous expression is an 
essential for adipocyte to function was investigated. The mRNA expression of PPARγ 
was decreased after 3 h treatment of TNFα and the expression was further decreased 
up to 50 % after 6 h (p<0.001). However, no further decrease was induced after 9 h 
treatment of TNFα. Thus, 6 h treatment was selected and used for further study.   
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Figure 12. Effect of TNFα on PPARγ expression in mature adipocytes. Fully 
differentiated 3T3-L1 adipocytes were serum-starved for 24 h and then treated 
with TNFα (10 ng/mL) for the indicated time periods in the presence of insulin 
(167 nM). Total RNAs were isolated and subject to RT-PCR as described in 
Methods. The expriment was repeated three times in duplicate and the data 
resented are relative values expressed in relation to endogenous β-actin 
(mean±S.E.). Significant difference was determined by independent t-test 
(*p<0.05 vs. control, **p<0.01vs. control, ***p<0.001 vs. control) 
 
3.5.6. TNFα increased its target proinflammatory genes expressed in mature 
adipocytes.  
To ascertain whether TNFα induces the mRNA expression of IL-6 and MCP1 
in adipocytes as observed during preadipocyte differentiation, TNFα-treated 
adipocytes were analyzed. As shown in Fig. 13, the mRNA expression of IL-6 and 
MCP1 were significantly increased after 6 h in adipocytes. IL-6 mRNA expression 
was upregulated nearly 13-fold (p<0.001). In addition, the mRNA expression of 
MCP1 was increased about 5-fold (p<0.001) compared to non-TNFα-treated 
adipocytes, suggesting TNFα induces the expression of inflammatory cytokines while 
impairing adipocyte functions.   
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Figure 13. TNFα increases the expression of IL-6 and MCP1 in mature adipocyte. 
Fully differentiated 3T3-L1 adipocytes were serum-starved for 24 h and then 
treated with TNFα (10 ng/mL) for 6 h in the presence of insulin (167 nM). Total 
RNAs were isolated and subject to RT-PCR as described in Methods. The 
expriment was repeated three times in duplicate and the data resented are 
relative values expressed in relation to endogenous β-actin (mean±S.E.). 
Significant difference was determined by independent t-test (*p<0.05 vs. control, 
**p<0.01vs. control, ***p<0.001 vs. control) 
 
3.5.7. Perilipin and GLUT4 were decreased by TNFα in mature adipcoytes.  
To assess the inhibitory effects of TNFα on adipocyte functions, the genes 
related to adipocyte functions such as lipid and glucose metabolism were analyzed 
(Fig. 14). The mRNA expression of perilipin and GLUT4 were significantly inhibited 
in the presence of TNFα (p<0.001). However, TNFα did not affect the expression of 
FAS and adiponectin, consistent with the observation that FAS and adiponectin 
expression are not affected by PPARγ expression (J. H. Choi et al., 2010; Tan et al., 
2005). Thus these data indicate that TNFα impairs adipocyte functions via PPAR 
inhibition.  
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Figure 14. TNFα does not affect the expression of FAS and adiponectin but alters 
perilipin and GLUT4 expression in mature adipocytes. Fully differentiated 
3T3-L1 adipocytes were serum-starved for 24 h and then treated with TNFα (10 
ng/mL) for 6 h in the presence of insulin (167 nM). Total RNAs were isolated 
and subject to RT-PCR as described in Methods. The expriment was repeated 
three times in duplicate and the data resented are relative values expressed in 
relation to endogenous β-actin (mean±S.E.). Significant difference was 
determined by independent t-test (*p<0.05 vs. control, **p<0.01vs. control, 
***p<0.001 vs. control) 
 
3.5.8. Lipid oxidation-related genes were inhibited in the presence of TNFα in 
mature adipocytes.  
To ascertain the inhibitory effects of TNFα on adipocyte function, lipid 
oxidation-related genes were also analyzed after 6 h treatment of TNFα. Unlike the 
data from preadipocyte differentiation, TNFα treatment significantly downregulated 
the mRNA expression of CPT1 and PGC-1α both in mature adipocytes (p<0.001), 
suggesting the differential modes of action of TNFα that induces adipocyte 
dysfunction through the inhibition of adipocyte PPARγ and preadipocyte 
differentiation. 
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Figure 15. Effects of TNFα on the mRNA expression of CPT1 and PGC-1α in 
mature adipocytes. Fully differentiated 3T3-L1 adipocytes were serum-starved 
for 24 h and then treated with TNFα (10 ng/mL) for 6 h in the presence of 
insulin (167 nM). Total RNAs were isolated and subject to RT-PCR as described 
in Methods. The expriment was repeated three times in duplicate and the data 
resented are relative values expressed in relation to endogenous β-actin 
(mean±S.E.). Significant difference was determined by independent t-test 
(*p<0.05 vs. control, **p<0.01vs. control, ***p<0.001 vs. control) 
 
3.5.9. Palmitic acid induced hypertrophic adipocytes concomitant with increased 
expression of proinflammatory cytokines.  
Since obesity is characterized by hypertrophic adipocytes and chronic 
inflammation state, in vitro TNFα treatment will represent acute inflammatory 
response of normal adipocytes. Thus, the characteristics of in vitro lipid-overloaded 
adipocytes which represent hypertrophic adipocytes in obesity were investigated to 
confirm the TNFα-induced characteristic changes in gene expression previously (Fig. 
8-15). To this end, adipocytes were exposed to palmitic acid (PA) at 250 µM to 
induce hypertrophic adipocytes that overexpress proinflammatory cyoktines such as 
TNFα as described in previous studies (Han et al., 2007; Kim et al., 2015). As shown 
in Fig. 16, PA-treated adipocytes showed a big lipid droplet and a bigger size of 
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adipocytes compared to nonPA-treated cells. In addition, hypertrophic adipocytes 
significantly increased the mRNA expression of TNFα (p<0.05) and IL-6 (p<0.001), 
suggesting that obesity-induced hypertrophic adipocytes are established in vitro. 
 
 
Figure 16. PA-induced in vitro hypertrophic adipocytes mimics adipose tissue 
low-grade inflammation in obesity. At day 8 after differentiation, the cells 
were exposed to PA at 250 µM for additional 6 days to induce hypertrophic 
adipocytes. Total RNAs were isolated and subject to RT-PCR as described in 
Methods. The expriment was repeated three times in duplicate and the data 
resented are relative values expressed in relation to endogenous β-actin 
(mean±S.E.). Significant difference was determined by independent t-test 
(*p<0.05 vs. control, **p<0.01vs. control, ***p<0.001 vs. control). 
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3.5.10. Hypertrophic adipocytes induced dysfunctional adipocyte phenotypes.  
To assess if chronic inflammatory state during the induction of adipocyte 
hypertrophy indeed induces adipocyte dysfunction as observed in in vitro TNFα 
treatment studies during preadipocyte differentiation and in mature adipocyte, the 
major genes for adipocyte function were analyzed, such as PPARγ, perilipin and 
adiponectin. As shown in Fig. 17, hypertrophic adipocytes showed a significant 
reduction in the levels of PPARγ (p<0.05), perilipin (p<0.01) and adiponectin 
(p<0.05), indicating that in vitro hypertrophic adipocytes are characterized by 
overexpression of proinflammatiory cytokines but by dysregulation of adipocyte 
functions.  
 
Figure 17. PA-induced changes in gene expression of PPARγ, perilipin and 
adiponectin. At day 8 after differentiation, the cells were exposed to PA at 250 
µM for additional 6 days to induce hypertrophic adipocytes. Total RNAs were 
isolated and subject to RT-PCR as described in Methods. The expriment was 
repeated three times in duplicate and the data resented are relative values 
expressed in relation to endogenous β-actin (mean±S.E.). Significant difference 
was determined by independent t-test (*p<0.05 vs. control, **p<0.01vs. control, 
***p<0.001 vs. control).  
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4. IN VIVO STUDY: THE ROLE OF TNFα IN HIGE-FAT DIET  
(HFD)-INDUCED OBESITY 
4.1. Materials 
Triglyceride content measurement kit was purchased from Sigma Chemical 
Co.(St Louis, MO, USA) and the fast SYBR real-time PCR master mix was obtained 
from ife Technologies (Grand Island, NY, USA). Antibodies against fatty acid 
binding protein 4 (FABP4), perilipin and fatty acid synthase (FAS) were purchased 
from Cell signaling technology (Beverly, MA, USA). Antibodies against peroxisome 
proliferator-activated receptor gamma (PPARγ), and β-actin were purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
4.2. Experimental design  
All experimental procedures were approved by the Institutional Animal Care 
and Use Committee of the Jean Mayer USDA human Nutrition Research Center on 
Aging at Tufts University. C57BL/6 mice were used in this study. At age of 6 weeks, 
the mice were divided into three groups (6 mice per group): wild-type mice 
administered with a low-fat diet (10% of total kcal as fat), WT-LF; wild-type mice 
administered with a high-fat diet (60% of total kcal as fat), WT-HF; TNFα knockout 
mice administered with a high-fat diet, TNFα KO-HF. Obesity was induced for 16 
weeks (from age of 6 to 18 weeks). At the time of sacrifice, adipose tissues were 
frozen in liquid nitrogen and stored at - 80˚C. 
 
4.3. Methods 
Ø Triglyceride (TG) content measurement. Liver TG contents were measured by TG 
content measurement kit from Sigma Chemical Co.(St Louis, MO, USA). Sample TG 
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contents were compared with a TG standard curve which is measured by a microplate 
reader (SpectraMax M2, Molecular Devices, Sunnyvale, CA) at 570 nm. 
 
Ø Quantitative real-time PCR. Total RNA was isolated with TRIzol® according to 
manufacturer’s protocol (Life technologies, Grand Island, NY). 1 µg of total RNA 
was used to synthesize cDNA using RevertAid First Strand cDNA Synthesis kit 
(Thermo Scientific, Waltham, MA). The reaction was performed with Fast SYBR® 
Green Master Mix containing 1 µM of primer pair and 100 ng of cDNA under 40 
cycles with each of 95 °C for 1 sec and 58 °C for 20 sec. Relative levels of the target 
mRNA expression were determined by ViiATM 7 real-time PCR system (Life 
technologies, Grand Island, NY), normalized to GAPDH or β-actin and calculated 
with the 2-(ΔΔnd) method. 
 
Ø Western blotting. Adipose tissues were lysed using RIPA buffer (Life technologies, 
Grand Island, NY) with protease and phosphatase inhibitor cocktail (Life technologies, 
Grand Island, NY) for 30 min in ice, and then centrifuged at 12,000 x g for 20 min at 
4 °C. The supernatants were taken into new tubes for protein quantitation assay using 
DCTM protein assay kit II (Bio-Rad, Hercules, CA). 50 µg of each lysates were 
separated on 10 % SDS-polyacrylamide gel and transferred to PVDF membranes. The 
membranes were blocked for 1 h at room temperature, washed 4 times with TBS-T 
for 5 min and incubated overnight with a primary antibody at 4 °C. The membranes 
were then washed 3 times with TBS-T and incubated with a secondary antibody at RT. 
To detect the target proteins, the membranes were incubated with ClarityTM Western 
ECL Blotting substrate (Bio-Rad, Hercules, CA) for 5 min using an Image Station 
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4000MM instrument (Carestream Health, New Heaven, CT). The band intensity was 
determined by ImageJ software (U.S. National Institutes of Health). 
 
4.4. Statistical analysis 
All statistical analyses were performed in Excel and statistical significances 
were evaluated with independent t-test. 
 
4.5. Results 
4.5.1. High-fat diet (HFD) for 16 weeks induced obesity but decreased adipose 
tissue functions via TNFα. 
 In order to examine if HFD administration for 16 weeks, which is relatively 
prolonged and chronic over-nutrition period, induces adipocyte dysfunction through 
TNFα production, adipogenic function-related genes such as PPARγ, perilipin and 
FAS and FABP4 were analyzed in adipose tissue. As shown in Fig. 18, HFD for 16 
weeks significantly inhibited the protein expression levels of PPARγ, perilipin, FAS 
and FABP4 (p<0.001), suggesting obesity-induced adipose tissue dysfunction. 
However, HFD-induced suppression of perilipin and FABP4, were in part restored 
and PPARγ was completely recovered in the absence of TNFα, suggesting HFD or 
TNFα itself is able to induce adipose tissue dysfunction but the inhibitory effects of 
TNFα is a PPARγ-dependent. 
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Figure 18. Changes in adipogenic protein expression in adipose tissue from LFD-
TNFα+/+ (WT-LF), HFD-fed TNFα+/+ (WT-HF) and HFD-fed TNFα-/- 
(TNFα KO-HF). A representative immunoblot showing PPARγ, perilipin, FAS 
and FABP4 protein levels in adipose tissues. The western blots are quantified by 
Image J software and presented as relative expression of control. Six mice were 
used in each analysis. Significant difference was determined by independent t-
test (*p<0.05 vs. WT-LF, **p<0.01vs. WT-LF, ***p<0.001 vs. WT-LF, 
#p<0.05 vs. WT-HF, ##p<0.01 vs. WT-HF, ###p<0.001 vs. WT-HF) 
 
4.5.2. TNFα inhibited adipose tissue PPARγ gene expression. 
 To confirm TNFα-induced changes in the gene expression, the adipogenic 
genes were analyzed by RT-PCR. Consistent with the protein data, mRNA expression 
levels of PPARγ and perilipin were significantly upregulated in the absence of TNFα, 
whereas the mRNA expression of FAS was not significant at p<0.05 despite an 
upward tendency. Also, these data are consistent with TNFα-treated mature adipocyte 
which represented a significant decrease in the mRNA expression of perilipin and 
PPARγ but not in FAS mRNA expression.  
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Figure 19. The mRNA expression of adipogenic genes such as PPARγ, perilipin, 
FAS in TNFα+/+ (WT-HF) and TNFα-/-(TNFα KO-HF). The data presented 
are relative values expressed in relation to endogenous β-actin (mean±S.E.). Six 
mice were used in each analysis. Significant difference was determined by 
independent t-test (*p<0.05 vs. WT-HF, **p<0.01vs. WT-HF, ***p<0.001 vs. 
WT-HF) 
 
4.5.3. Obesity-induced TNFα inhibited adipose tissue functions.  
 To ascertain the role of TNFα in adipose tissue function, glucose metabolism 
and triglyceride (TG) dynamics-related genes were analyzed. As shown in Fig. 20, 
glucose metabolism-related genes, TNFα deficiency significantly upregulated the 
mRNA expression adiponectin and GLUT4 at least 20-fold (p<0.05). In addition, the 
marker genes for TG synthesis (DGAT1) and TG breakdown (ATGL) were 
significantly increased in the absence of TNFα (p<0.001), suggesting that TNFα plays 
an important role in adipose tissue dysfunction in obesity.  
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Figure 20. The mRNA expression of GLUT4, adiponectin, DGAT1 and ATGL in 
TNFα+/+ (WT-HF) and TNFα-/-(TNFα KO-HF). The data presented are 
relative values expressed in relation to endogenous β-actin (mean±S.E.). Six 
mice were used in each analysis. Significant difference was determined by 
independent t-test (*p<0.05 vs. WT-HF, **p<0.01vs. WT-HF, ***p<0.001 vs. 
WT-HF) 
 
4.5.4. Obesity-induced TNFα induced hepatic TG accumulation.  
 Since a loss of TNFα in HFD-induced obese mice decreased circulating FFAs 
and hepatic TG contents (Salles et al., 2012), we next investigated if TNFα-induced 
adipose tissue dysfunction increases hepatic accumulation. To this end, hepatic TG 
contents among the groups were first analyzed. As shown in Fig. 21, HFD 
significantly increased hepatic TG contents (p<0.05), whereas the TG contents in 
HFD-fed TNFα-/- mice were significantly lowered as statistically similar as to LFD-
fed TNFα+/+, suggesting that TNFα is the causative factor that increases hepatic lipid 
deposition in obesity.  
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Figure 21. Hepatic TG contents from LFD-TNFα+/+ (WT-LF), HFD-fed 
TNFα+/+ (WT-HF) and HFD-fed TNFα-/- (TNFα KO-HF). Hepatic TG was 
extracted and analyzed using TG content measurement kit. Data are expressed as 
µg/mg of liver tissue and represent the means±S.E. Six mice were used in each 
analysis. Significant difference was determined by independent t-test (*p<0.05 
vs. WT-LF, **p<0.01vs. WT-LF, ***p<0.001 vs. WT-LF, #p<0.05 vs. WT-HF, 
##p<0.01 vs. WT-HF, ###p<0.001 vs. WT-HF) 
 
4.5.5. Obesity-induced TNFα increased hepatic TG content.  
 To investigate if TNFα-induced hepatic lipid engorgement is associated with 
adipose tissue dysfunction, lipogenic genes such as FAS and SCD1 were analyzed 
from the liver. First, TNFα mRNA expression was analyzed and decreased in TNFα-
deficient mice as expected. As shown in Fig. 22, the mRNA expression levels of FAS 
and SCD1 were significantly decreased in the liver from HFD-fed TNFα+/+ mice 
(p<0.01), suggesting that HFD itself decreases de novo lipogenesis genes, FAS and 
SCD1 due perhaps to abundant dietary free fatty acids in HFD but increases TG 
synthesis through the utilization of circulatory free fatty acids (Duarte et al., 2014). 
However, the reduction of de novo lipogenesis-related genes was further decreased in 
the absence of TNFα, suggesting obesity-induced TNF production causes adipose 
tissue dysfunction that imposes the metabolic burden to the liver. 
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Figure 22. The mRNA expression of TNFα, FAS and SCD1 in liver tissues from 
LFD-TNFα+/+ (WT-LF), HFD-fed TNFα+/+ (WT-HF) and HFD-fed TNFα-
/- (TNFα KO-HF). The data presented are relative values expressed in relation 
to endogenous β-actin (mean±S.E.). Six mice were used in each analysis. 
Significant difference was determined by independent t-test (*p<0.05 vs. WT-
LF, **p<0.01vs. WT-LF, ***p<0.001 vs. WT-LF, #p<0.05 vs. WT-HF, 
##p<0.01 vs. WT-HF, ###p<0.001 vs. WT-HF) 
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5. SUMMARY 
5.1. In vitro study: The effects of TNFα in adipocyte functions 
 
In summary, we examined the role of TNFα in adipocyte functions. The 
results demonstrate that TNFα treatment induces dysfunctional adipocytes through the 
inhibition of adipocyte PPARγ and preadipocyte differentiation. In addition, our data 
indicate that PA-induced in vitro hypertrophic adipocytes are dysfunctional, due 
perhaps to overexpression of TNFα. This conclusion is supported by the data from 
TNFα-treated adipocytes that showed a consistent data with hypertrophic adipocytes. 
Therefore, TNFα-induced changes in gene expression during preadipocyte 
differentiation and in mature adipocytes provide a molecular understanding for the 
development of adipocyte dysfunction.. 
 
 
Figure 23. The schematic diagram depicting the possible mode of action of TNFα 
in adipocytes.  
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5.2. In vivo study: The role of TNFα in high-fat diet (HFD)-induced obesity 
 
In summary, we examined the potential role that TNFα plays in adipocyte 
metabolism and function in vivo. The results indicate the significant contribution of 
obesity-induced TNFα production to adipocyte dysfunction, hepatic lipid deposition 
and insulin resistance. Also, this study clearly indicates that diet itself is a negative 
mediator that suppresses de novo lipogenesis in the liver and adipose tissue. 
 
 
Figure 24. The schematic diagram depicting the underlying mechanisms by 
which TNFα induces insulin resistance in obesity.  
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6. DISCUSSION 	
 In obesity, chronic low-grade inflammation has been implicated to induce 
insulin resistance (IR) that links obesity to type 2 diabetes (T2DM) (Samad & Ruf, 
2013). Recent research studies indicate that tumor necrosis factor α (TNFα) is a 
causative factor of acquired IR and with it come many risk factors of T2DM, such as 
elevated free fatty acids (FFAs) and hepatic deposition (Bouter, Geary, Langhans, & 
Asarian, 2010; Salles et al., 2012). However, the molecular mechanisms that underlie 
the deleterious action of TNFα in obesity have been unclear.  
  A direct interaction between TNFα and insulin resistance has been implicated, 
as studies in obese and diabetic rodents indicate that the absence of TNFα improves 
the resistance to the action of insulin to stimulate peripheral glucose uptake 
(Hotamisligil et al., 1993; Uysal et al., 1997). This is further supported by the 
demonstration that TNFα impairs the signaling capacity of the insulin receptor in 
adipose tissue in vivo and adipocytes in vitro through the blockage of tyrosine 
phosphorylation of the insulin receptors (Hotamisligil et al., 1996; Hotamisligil et al., 
1993; Stephens et al., 1997). In addition, TNFα increases the mobilization of FFAs 
into the circulation, hepatic lipid deposition and elevated concentrations of 
inflammatory cytokines such as MCP1 and IL-6 in HFD-induced obese mice (Salles 
et al., 2012), suggesting that the association between TNFα and T2DM is a causal 
relationship. However, how TNFα is interrelated with the risk factors for T2DM 
should be determined. 
 The importance of adipose tissue function in the body has been brought up by 
the observation that dysfunctional adipose tissue elevates circulating concentration of 
FFAs and causes dramatic lipid engorgement in the liver and insulin resistance 
(Moitra et al., 1998; Sovik et al., 1996). Adipose tissue function is maintained by 
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adipocytes which constitutes almost adipose tissue. Also, preadipocyte differentiation 
is required to maintain functional adipocytes. In this context, TNFα has been 
implicated to compromise adipose tissue function through the downregulation of 
PPARγ expression which is an essential transcriptional factor for preadipocyte 
differentiation and mature adipocyte functions such as lipid and glucose metabolism. 
Indeed, our data indicate that TNFα inhibited preadipocyte differentiation and mature 
adipocyte functions through PPARγ in vitro, consistent with previous studies (Chae & 
Kwak, 2003; Ruan et al., 2002). In addition, in vitro hypertrophic adipocytes had a 
significant decrease in PPARγ but overexpressed TNFα and IL-6 mRNAs. Consistent 
with in vitro data, TNFα-/- fed HFD had a significant increase in the genes such as 
PPARγ, perilipin, DGAT1 and ATGL, suggesting that the development of the 
inflammatory state in obesity is associated with adipocyte dysfunction. However, 
HFD per se is a negative mediator of adipose tissue function as TNFα deficiency in 
part restored lipogenic genes such as perilipin, FAS and FABP4.  
In addition, the normal secretion of adipokines such as adiponectin is the role 
of adipose tissue as endocrinal organ. Adiponectin is the important cytokine to 
enhance the whole body insulin sensitivity, but especially hepatic insulin sensitivity 
(Kawano & Arora, 2009; Pagano et al., 2005). Indeed, the circulating concentration of 
adiponectin is decreased but hepatic insulin resistance and lipid deposition are 
increased in obesity and T2DM (Kadowaki et al., 2006). To our knowledge, however, 
it has not been previously reported which factor or factors alter plasma adiponectin 
levels in obesity and T2DM. Our in vitro data indicate that TNFα treatment 
significantly inhibited the mRNA expression of adiponectin during preadipocyte 
differentiation and in mature adipocytes and that hypertrophic adipocytes had a 
decrease in adiponectin mRNA expression. In addition, adiponectin mRNA 
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expression significantly increased but hepatic deposition decreased in HFD-fed 
TNFα-/-, suggesting that TNFα-induced adipocyte dysfunction is associated with a 
decrease in adiponectin expression. However, it has been reported that circulating 
adiponectin concentration is not increased in TNFα-deficient mice fed HFD for 4 
weeks (Bouter et al., 2010). This could be the difference in HFD feeding period that 
can also differentiate the profound effects of TNFα on adipocyte because the 
circulating levels of TNFα is increased in proportion to the severity of insulin 
resistance.    
 In conclusion, the present study provides the new insight into the casual 
relationship between inflammation and insulin resistance in obesity. Our data indicate 
the contribution of obesity-induced TNFα to adipocyte dysfunction that can increase 
the risk factors such as the elevated circulating FFAs levels, hepatic deposition, 
insulin resistance and decreased circulating concentration of adiponectin, for T2DM.   
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